Intesticort (Budesonide)

Budesonide is a glucocorticoid that binds to intracellular glucocorticoid receptors, altering gene transcription to suppress pro‑inflammatory cytokines, inhibit leukocyte migration, and stabilise lysosomal membranes. This cascade reduces local inflammation in the gastrointestinal tract, providing symptom relief in ulcerative colitis and proctitis.

The appropriate dose of Intesticort is determined by the prescribing clinician based on disease severity, patient response, and clinical guidelines. Dosage may vary, and patients should follow the exact instructions provided by their healthcare professional without deviation.

Safety data for budesonide rectal formulations in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies any possible risk to the fetus or infant. Women who are pregnant, planning pregnancy, or breastfeeding should discuss risks and alternatives with their physician.

To request Intesticort, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Intesticort delivers budesonide, a high‑potency glucocorticoid with extensive first‑pass metabolism, resulting in lower systemic exposure compared with some oral steroids. Compared with mesalamine enemas, budesonide may provide faster symptom control in acute inflammation, though choice depends on patient tolerance, disease extent, and physician preference.

Intesticort should be stored at temperatures below 25 °C, in its original packaging, protected from moisture and direct sunlight. Do not freeze the product. Keep it out of reach of children and ensure the packaging remains intact until use.

Intesticort is administered rectally, typically as a suppository or enema. The patient should follow the healthcare provider’s instructions, inserting the dose into the rectum in a comfortable position, and retain it for the recommended period to allow optimal drug absorption.

Serious risks include adrenal suppression leading to systemic corticosteroid effects, severe infections, allergic reactions such as anaphylaxis, and, rarely, colonic perforation. Patients should be monitored for signs of infection, unexplained fatigue, or severe gastrointestinal symptoms and report them promptly to their physician.

Intesticort is contraindicated in individuals with known hypersensitivity to budesonide or any excipients in the formulation. It should also be avoided in patients with active severe infections, untreated bowel obstruction, or those who are currently using systemic corticosteroids at high doses without medical supervision.